Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), announced positive results from Trial CL07-001, a thorough QT study of the Company's novel once-a-day oral antibiotic, cethromycin. This study was conducted to evaluate the cardiac safety of cethromycin and to enhance the safety database for the Company's upcoming New Drug Application (NDA) submission for cethromycin to treat community acquired pneumonia (CAP). The U.S.
(more...)